antibiotic/obesity

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, is named 1210469-US2.txt, and is approximately 2,296 bytes in size. FIELD OF THE INVENTION The present

FIELD OF THE INVENTION The present invention relates to microbiology and the manipulation of intestinal microbiota to modify dietary energy uptake in a human subject. More specifically, the present invention provides means and techniques to scavenge short-chain fatty acids, such as acetate, before

FIELD OF THE INVENTION This invention relates to the treatment of obesity primarily, but not exclusively, in the field of human medicine. GENERAL BACKGROUND Considerable interest has been shown in recent years in the use of prostaglandin (PG) precursors in medicine. For various reasons it is not

FIELD OF THE INVENTION The present invention relates to characterizing changes in mammalian intestinal microbiota associated with high-fat and low-fat diets and with diets containing hydroxypropylmethylcellulose (HPMC) and related methods for diagnosing, preventing and treating obesity and related

This disclosure contains material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the U.S. Patent and Trademark Office patent file or records, but otherwise

FIELD OF THE INVENTION The present invention relates to a composition comprising one or more oxalate degrading enzymes for delivering the enzymes in active form to the stomach, where the one or more oxalate degrading enzymes exert their effect. Thus, the present invention provides means for reducing

The present invention relates to bacterial ClpB protein and ClpB expressing bacteria and their impact on eating disorders. The invention further relates to compositions comprising antibiotic directed against at least one ClpB expressing bacterium as well as probiotics not expressing ClpB protein and

FIELD OF THE INVENTION The present invention relates to the development of platform technology for targeted, controlled delivery of oral enhanced probiotics for various indications, including for example the active and prophylaxis treatment of Clostridium difficile Infection as well as Metabolic

FIELD OF THE INVENTION The present invention relates to characterizing changes in mammalian gastrointestinal microbiota associated with antibiotic treatment and various disease conditions (such as obesity, metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, glucose

FIELD OF THE INVENTION This invention relates to methods for diagnosing and treating sequellae related to human dormancy syndrome, including cancer and autoimmune disease. In particular, this invention relates to treating cancer and/or autoimmune diseases using combination therapy using

FIELD OF THE INVENTION This invention relates to methods for diagnosing and treating sequellae related to human dormancy syndrome, including cancer and autoimmune disease. In particular, this invention relates to treating cancer and/or autoimmune diseases using combination therapy using

FIELD OF THE INVENTION The present invention relates to the development of platform technology for targeted, controlled delivery of oral enhanced probiotics for various indications, including for example the active and prophylaxis treatment of Clostridium difficile Infection as well as Metabolic

FIELD OF THE INVENTION The present invention is in the field of methods for inducing weight loss and treatment of gastrointestinal disorders through mechanical and physiological means using polymers which are pH dependent by inducing the appropriate stomach pH and by further using the polymers in

FIELD OF THE INVENTION This invention relates to the treatment of various diseases and disorders primarily, but not exclusively, in the field of human medicine and to pharmaceutical and dietary compositions for use therein. GENERAL BACKGROUND Considerable interest has been shown in recent years in